Liver

Treatment

Unresectable

1st Line

HEP0071
Randomized Phase II Atezolizumab and Bevacizumab in Combination with SRF388 or Placebo in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

PI: Chen
Surface Oncology, Inc.

HEP0068
Selective Internal Radiation Therapy (SIRT) using SIR-Spheres® Y-90 Resin Microspheres on Duration of Response (DoR) and Objective Response Rate (ORR) in Unresectable Hepatocellular Carcinoma (HCC)

PI: Louie Sirtex Medical Inc.

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu